Why the study?
Platelets support pathological thrombosis and neoplastic proliferation, prompting investigators to test whether selectively silencing hepatic thrombopoietin could safely reduce platelet count and alter tumor progression.
Does THPO-ASO reduce platelet count and delay breast cancer progression in transgenic MMTV-PyMT mice?
Population
Mice, a baboon, and 6-week-old transgenic MMTV-PyMT mice
Comparison
THPO-ASO administration vs untreated controls
Design
Preclinical animal study
Key result
THPO-ASO administration reduced blood platelet count and delayed the progression of metastatic breast cancer in transgenic MMTV-PyMT mice compared to untreated controls.
Authors
Loading...
Platelet count in normal range may associate with thrombosis or cancer; leaves open whether cMPL modulation merits prospective trials.
Does THPO-ASO reduce platelet count and delay breast cancer progression in transgenic MMTV-PyMT mice?
Pharmacological reduction of platelet count using THPO-ASO is feasible and delays the progression of platelet-dependent pathological processes like breast cancer metastasis in a preclinical model.
Shirai et al. (2019) studied Breast cancer. THPO-ASO vs. untreated controls was evaluated on Average time to euthanasia at 2 cm3 combined palpable tumor volume. THPO-ASO administration reduced blood platelet count and delayed the progression of metastatic breast cancer in transgenic MMTV-PyMT mice compared to untreated controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: